“sirna-therapeutics” Archives

Entry Author Date Location
Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug 09/20/17 Boston
East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More 06/12/15 Boston
New Research Could (Finally) Remove RNAi’s Commercial Limitations 11/17/14 National
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
Alnylam Wheels, Deals, and Gets $700M Investment From Genzyme 01/13/14 Boston
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up 05/09/13 Texas
A Biotech Innovation Supply Chain: Reality or Fantasy? 04/22/13 National
Merck Shuts Down RNAi Research Center in SF, Cutting 50 Jobs 07/29/11 San Francisco
ProNAi Therapeutics Advances Gene-Silencing Cancer Drug, Marina Biotech Provides Delivery Package 09/28/10 Detroit Ann Arbor
Dicerna Pharma Gets $25M Boost to Develop Next-Gen Gene Silencing Drugs 08/11/10 Boston
Doug Fambrough Reduces Role at Oxford Bioscience Partners, Becomes CEO of Portfolio Company Dicerna Pharma 05/06/10 Boston
Vertex CEO on Building a Blockbuster, Genzyme Investor on Fixing Up the Firm, Cubist CEO on Pipeline and Patent Challenges, & More Boston-Area Life Sciences News 01/28/10 Boston
Accelerator Slowed Down, Inside the Latest Seattle Genetics Deal, Ekos Finds New Use, & More Seattle-Area Life Sciences News 01/28/10 Seattle
Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery 01/21/10 National
Surprised? Oxford Bioscience Partners Lands, Briefly, on Dreaded List of “VC Walking Dead” 03/20/09 Boston
Dicerna Aims to Gain Foothold in RNAi World With More Potent, Longer-Lasting Gene Silencers 01/30/09 Boston
MDRNA Cuts Executive Pay, Freezes Salaries as Cash Runs Out 01/23/09 Seattle
Got Dry Eye? Take Fish Oil. Resolvyx Moves First Compound Into Human Test 11/20/08 Boston
Page 1 of 1